Natixis’s Amphastar Pharmaceuticals AMPH Stock Holding History

Natixis’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13,400	Closed	-$829K	–	1007
2023 Q4	$829K	Buy	+13,400	New	+$704K	0.01%	554

Other funds holding AMPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Natixis's AMPH Position: Q1 2024 in Review

Natixis sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 13,400 shares — an estimated $829K sold.

Natixis first reported a position in AMPH in Q4 2023 and held it in 1 quarter. The position peaked at $829K in Q4 2023. 271 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

Natixis reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Natixis sold 13,400 Amphastar Pharmaceuticals shares in Q1 2024, an estimated $829K.
Natixis first reported a position in Amphastar Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Natixis's Amphastar Pharmaceuticals position peaked at $829K in Q4 2023.
271 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.